Eisai & Biogen Secure Leqembi China Maintenance Approval
CompanyDrug

Eisai & Biogen Secure Leqembi China Maintenance Approval

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors
CompanyDrug

HanX Biopharmaceuticals Secures NMPA Approval for HX044‑HX008 PD‑1 Therapy Combination in Advanced Solid Tumors

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India
CompanyDeals

Novatim Partners with VRise to Launch KQ‑2003 CAR‑T in India

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis
CompanyDrug

CMS Announces Phase 3 Success of Ruxolitinib Cream in Atopic Dermatitis

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition
Company

Merck Names Kai Beckmann as Incoming CEO, Signals Smooth Leadership Transition

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says
Policy / Regulatory

Trump’s New Pharmaceutical Tariffs Will Be Limited to 15% for EU and Japan, White House Says

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials
CompanyDigital

Beijing Unicet’s QH104A Receives Chinese NMPA Approval for CNS Solid‑Tumor Clinical Trials

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration
CompanyDeals

Wolters Kluwer and the Chinese Academy of Medical Sciences Sign AI‑Driven Medical‑Information Collaboration

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor
Drug

Leo Pharma Secures First Greater Bay Area Prescription for Anzupgo, a Novel Topical JAK Inhibitor

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development
CompanyDeals

Shanghai MicuRx and GenScript’s ProBio Unit Sign Strategic Deal to Accelerate Antibody‑Drug Conjugate (ADC) Development

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign
Policy / Regulatory

NHSA Launches 100‑Day Medical‑Insurance Fraud Crackdown Campaign

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China
CompanyDrug

CSPC Pharma Secures NMPA Approval for Lecanemab Biosimilar, First of Its Kind in China